Compare Flux Power Holdings Inc (FLUX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Novartis AG — how do they compare? Flux Power Holdings Inc trades at $0.47 (market cap $9.97M), while Novartis AG trades at $143.49 (market cap $268.57B). The key difference: Novartis AG is far larger — about 26937.8× Flux Power Holdings Inc's market cap, and Novartis AG pays a 3.31% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 20 Days and Novartis AG for 82 Days on average.
| FLUX | NVS | |
|---|---|---|
Market Cap | $9.97M | $268.57B |
Volume | 817,320 | 1,532,573 |
Sector | Industrials | Health |
52-Week High | $6.66 | $168.62 |
52-Week Low | $0.41 | $121.80 |
Typical Hold Time | 20 Days | 82 Days |
Enterprise Value | $18.18M | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.49, down 0.55% today, amid ongoing acquisition interest from Solidion Technology. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal declining revenue from $66M in 2025 to $42M in 2026 and persistent net losses. Despite unanimous analyst buy ratings, recent earnings misses and negative profitability metrics (-17.68% net margin) highlight operational challenges.
The outlook remains speculative with acquisition potential offering upside, but fundamental weakness and cash flow concerns pose significant risks. Investors face a binary outcome between takeover premium and continued operational losses in the competitive energy storage sector.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
